Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibTalaromyces (Penicillium) marneffei infection in non-HIV-infected patientsJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyManaging Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsEfficacy of ruxolitinib for myelofibrosis.Safety evaluation of ruxolitinib for treating myelofibrosis.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsRuxolitinib: a review of its use in patients with myelofibrosis.Safety considerations when treating myelofibrosis.Case-report: EBV driven lymphoproliferative disorder associated with RuxolitinibMapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.Definition and management of ruxolitinib treatment failure in myelofibrosis.Immunological Consequences of JAK Inhibition: Friend or Foe?Pacritinib: a new agent for the management of myelofibrosis?JAK2 inhibitors for myeloproliferative neoplasms: what is next?Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.Treatment of Myelofibrosis: Old and New Strategies.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidencePneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.Ruxolitinib-associated infections: A systematic review and meta-analysis.Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.Disseminated tuberculosis associated with ruxolitinib.JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
P2860
Q26750696-14A974B0-EEA2-41F5-ACD4-DC1AB8A4956DQ26767153-F57A79CA-3397-4A6C-88FD-A2DBB50B7D7DQ26782539-0DA8043E-715F-4AB7-97C0-1A64301D8DAAQ26851417-5EFFA6DA-D3E0-447A-9130-801B8E3F22E1Q26996258-8039CA4F-20D0-4ED1-9AD4-BD45F4D7576FQ28070090-5DE609EF-9FF3-4FAB-977F-C50BD6C989E4Q28073296-215C9179-32A1-4C80-9D34-0F7C84D597B0Q33415489-0EF9B1D4-C009-4975-AEB6-FA87F0028B9EQ33415731-D4F57F8D-35F9-40A9-A2DE-18EDA54396FDQ33417217-EBD9E04F-7E15-4815-99D3-C3162067EAA1Q33419865-3C972683-64B8-4F94-9039-F7B6271D3CC9Q33432285-0576C52E-C73E-4186-AFC4-668B79E9769AQ35689225-22F494C2-F505-4935-AF4C-BE06B5B16A2FQ36207245-B98B9749-0615-47B1-B4EB-AB568988954FQ37035925-74C57572-7E63-4AE8-A648-6D768EBFF3E4Q37679267-F896239B-2B1C-4AE4-81F6-3D27519B6511Q38287012-01F612D7-FF0C-4165-B466-FFE11D909F96Q38570383-C3BFDF4E-9A16-4AC5-BA48-2248A021BACDQ38590232-4FE9F38B-BA82-4458-91DB-2B1CD90EADCCQ38684435-62E75D1E-1DFD-4044-AAEF-4088FF7442ADQ38723484-0BB338ED-0B07-4579-8AEA-1CFE3E565903Q38814941-33A795C1-E2CF-44ED-972E-9C4F3E851750Q38938526-9ABBD53F-971F-4273-8991-FEC42B4B1465Q39349869-58978F1B-FD43-447D-B89D-533C10A52B59Q39554738-120F17DA-96B9-4862-B296-FB9B928C4760Q40602395-DD66F02F-7B32-4A54-B96D-974B85ABCBE7Q40692620-C11D868D-5BEC-4AE8-9936-7E77A3024A18Q41160178-E3F177FC-1DD5-4FE4-9433-CBDCA4F3309AQ44215080-38DC487F-C569-4C67-A988-F9E6204640B7Q47564349-CD5DC31D-6CC7-49FC-B129-3D5477A4203AQ48278553-BAA75689-8A32-42CE-A0B0-1D3D57E71CEBQ49567544-F778E219-21AD-4CBD-A75A-947FF3111D48Q52813540-8132DB12-5018-4022-ABD3-5AF92A919DECQ54250506-179A913A-5DE2-4267-AD71-594B64FF9532Q54254821-4831CC40-51E8-4E01-8AD1-50B88D0E2CF6Q54323036-E9B6C41B-A94D-4291-87A9-8DCACB0E3E4EQ54369040-9281E2EA-F50D-4AE3-9ADD-CE206EF29051Q54374933-CC9E8983-EBED-493D-B20E-7E0E2F682648Q56970836-57D9772B-D13A-4691-A7F2-4A1F295CBF0E
P2860
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@en
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@nl
type
label
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@en
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@nl
prefLabel
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@en
Reactivation of hepatitis B vi ...... a patient with myelofibrosis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Reactivation of hepatitis B vi ...... n a patient with myelofibrosis
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2013.235
P577
2013-08-09T00:00:00Z
P5875
P6179
1031321114